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Introduction: Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE type I) or dysfunction (C1-INH-HAE
type II) is a rare disease characterized by recurrent episodes of edema with an estimated frequency of 1:50,000 in
the global population without racial or gender differences. In this study we present the results of a nationwide
survey of C1-INH-HAE patients referring to 17 Italian centers, the Italian network for C1-INH-HAE, ITACA.
Methods: Italian patients diagnosed with C1-INH-HAE from 1973 to 2013 were included in the study. Diagnosis
of C1-INH-HAE was based on family and/or personal history of recurrent angioedema without urticaria and on
antigenic and/or functional C1-INH deficiency.
Results: 983 patients (53% female) from 376 unrelated families were included in this survey. Since 1973, 63 (6%)
patients diagnosed with C1-INH-HAE died and data from 3 patients were missing when analysis was performed.
Accordingly, the minimum prevalence of HAE in Italy in 2013 is 920:59,394,000 inhabitants, equivalent to 1:64,935.
Compared to the general population, patients are less represented in the early and late decades of life: men start
reducing after the 5th decade and women after the 6th. Median age of patients is 45 (IQ 28-57), median age at
diagnosis is 26 years (IQ 13-41). C1-INH-HAE type 1 are 87%, with median age at diagnosis of 25 (13-40); type 2
are 13% with median age at diagnosis of 31 (IQ 16-49). Functional C1INH is ≤50% in 99% of patients. Antigen
C1INH is ≤50% in 99% of type 1. C4 is ≤50% in 96% of patients. The chance of having C1-INH-HAE with C4
plasma levels >50% is < 0.05.
Conclusion: This nationwide survey of C1-INH-HAE provides for Italy a prevalence of 1:64,935. C1-INH-HAE patients
listed in our database have a shorter life expectancy than the general population. An increased awareness of the
disease is needed to reduce this discrepancy. Measurement of C4 antigen can exclude diagnosis of C1-INH-HAE
with an accuracy > 95%. This parameter should be therefore considered for initial screening in differential diagnosis
of angioedema.
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Hereditary angioedema (HAE) due to C1 Inhibitor
(C1-INH) deficiency (C1-INH-HAE) is a rare auto-
somal dominant disease due to reduced C1-INH
plasma levels (C1-INH-HAE type I) or to the presence
of a dysfunctional C1-INH (C1-INH-HAE type II) [1].
C1-INH-HAE type I is estimated to occur in approxi-
mately 85% of patients, type II occurs in the remaining
15%. C4 is reduced in both C1-INH-HAE type I and II
while C3 is normal [2]. The disease is caused by muta-
tion in C1-INH gene (SERPING1). De novo mutants, i.
e. the subjects whose parents have a normal C1-INH,
can be identified in approximately 25% of the families
[3]. The deficiency of C1-INH results in uncontrolled
activation of the contact system and release of bradyki-
nin, the mediator of increased vascular permeability
and angioedema manifestations [4,5]. C1-INH-HAE
manifests with recurrent episodes of edema of the skin,
gastrointestinal tract and upper airway. The disease is
disabling and laryngeal edema can lead to asphyxiation
and death if left untreated [2].
Data on the prevalence of C1-INH-HAE are sparse.
The estimated frequency worldwide reported in
literature varies from 1 every 10,000 to 1 every
150,000 persons without racial or gender differences
[6-8]. A nationwide survey in Denmark, based on 76
HAE patients, reported a minimum prevalence of
1:70,922 inhabitants [9]. Previous Norwegian and
Spanish studies based on 67 and 444 patients respect-
ively found a minimal prevalence of 1:66,225 and
1:91,743 inhabitants [10,11]. Two more recent surveys
in Sweden and in Slovenia based respectively on 145
and 17 patients reported a prevalence of 1:66.000 and
1:105,263 [12,13].
Since C1-INH-HAE is a genetic disease, the deficiency
of C1-INH is present from birth. Nevertheless a minority
of patients have perinatal angioedema symptoms. Pa-
tients typically begin to present clinical manifestations in
childhood and attacks frequency often increase around
puberty. Before the second decade of life the majority of
patients manifest symptoms of angioedema [14]. Due to
the rarity of the disease and to the fact that the clinical
symptoms overlap with those of other forms of
angioedema, C1-INH-HAE is frequently misdiagnosed.
Consequently C1-INH-HAE patients may experience
considerable delay between first symptoms and diagno-
sis. In a recent international observational study analyz-
ing data of patients eligible for Icatibant treatment
(Icatibant Outcome Survey, IOS) conducted in 8
European countries the mean delay in diagnosis of C1-
INH-HAE patients was 12.8 years [15]. Previous
nationwide surveys in France, Spain, and Denmark have
reported mean delays in diagnosis of 12, 13.1 and
16.3 years, respectively [9,10,16].In 1973 Agostoni et al. reported the first Italian family
with C1-INH-HAE [17]. After that few centers in Italy
have been active in diagnosing and treating this disease
[14,18]. In 2007 a multidisciplinary panel of Italian ex-
perts in C1-INH-HAE met for a Consensus Conference
held in Torino to define Italian guidelines for the diag-
nosis and therapy of C1-INH-HAE [19]. More recently,
in 2012 an Italian network for C1-INH-HAE (ITACA)
was established. ITACA, working together with the
Italian Hereditary Angioedema Patients’Association, col-
lected data from C1-INH-HAE patients referring to 17
centers active in Italy. Here we provide the results of the
analysis of these aggregate data.Methods
Patients
Patients diagnosed with C1-INH-HAE at one of the 17
Italian centres from 1973 to December 2013 were in-
cluded in the study. Diagnosis of C1-INH-HAE was
based on personal and/or family history of angioedema
and on C1-INH functional or antigenic plasma levels
≤50% of normal. All patients gave informed consent to
use their anonymized data.Italian population
Data on demografic characteristics of the Italian general
population were collected from the Italian Institute for
Statistic (December 2013), www.istat.it.Data collection
For each patient the following information were col-
lected from medical records: date of birth, date of diag-
nosis, condition (dead or alive), plasma levels of C1-INH
and C4 at diagnosis. Patients were not on prophylactic
treatment when complement parameters were measured.
Independent families were identified and the first diag-
nosed member of a family was considered as proband.Laboratory methods
C1-INH antigenic and C4 were quantified using radial
immunodiffusion or nephelometry; C1-INH function was
measured using a chromogenic or an immunoenzimatic
assay. Results were normalized as percentage of normal
value (functional C1-INH normal range 70-130%; anti-
genic C1-INH normal range 70-115%; antigenic C4 nor-
mal range 60-140%).Diagnosis of C1-INH-HAE Type I and II
Patients were diagnosed as C1-INH-HAE type I when
functional and antigenic C1-INH were ≤ 50% of normal,
and as type II when functional C1-INH was ≤50% and
antigenic was >50% of normal.
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Descriptive analysis of data from the Italian C1-INH-HAE
population was performed; results were reported as mean,
median, 25th and 75th percentiles range for each param-
eter. Differences in decade from C1-INH-HAE population
and Italian population were analyzed using Chi square test
at the 95% significant level and p-value < 0.05.
Results
Overall 983 patients (53% female) with C1-INH-HAE
from 376 unrelated families were included in this ana-
lysis. Since 1973, 63 (6%) patients died; furthermore data
from 3 patients were missing when analysis were per-
formed. Accordingly, the minimal prevalence of C1-
INH-HAE in Italy in 2013 is 1.54:100,000 inhabitants,
equivalent to a prevalence of 1:64,935. Median age of pa-
tients is 45 (IQ 28-57), median age at diagnosis is
26 years (IQ 13-41). The majority of patients, 859 (87%),
have C1-INH-HAE type I with median age at diagnosis
of 25 (13-40); patients with type II are 124 (13%) with
median age at diagnosis of 31 (IQ 16-49). Demographic
characteristics and laboratory assessments are summa-
rized in Table 1. Comparing the distribution per de-
cades of life of patients and of the Italian population we
found that patients are less represented in the first
decade and after the 7th decade compared to Italian
population (p < 0.05) (Figure 1).
Of the 367 unrelated families, 338 (92%) have type I
and 53 type II. “Families” with only one subject diag-
nosed as C1-INH-HAE are 157 (43%). The median age
of probands at diagnosis is 34 years. Analyzing 5 year pe-
riods, starting from the first diagnosis in the seventies, the
number of new probands increased until 1995 and
remained stable afterwards (Figure 2). Functional C1-INH
is ≤50% in 99% of patients. Antigen C1INH is ≤50% in
99% of type 1 patients. C4 antigen is ≤50% of normal in
96% of patients.
Discussion
This first nationwide survey of C1-INH-HAE in Italy
provides a minimum prevalence of 1: 64,935, the highest
value ever registered for this disease compared toTable 1 Demographic characteristics and laboratory assessme
Type I
Patients (%) 859 (87%)
Gender (M/F) 407/452
Median age (years) 44
Median age at diagnosis (years) 25
Antigenic C1-INH, median value (%) 21 (IR 13-25)
Funcitional C1-INH, median value (%) 20 (IR 10-30)
Antigenic C4, median value (%) 20 (IR 10-25)previous studies. Assuming that our centres collected
data on the majority of Italian C1-INH-HAE population,
patients not referring to these centres or not diagnosed
certainly exist. It is therefore very likely that the real
prevalence of C1-INH-HAE is higher approaching the
prevalence of 1:50,000 usually reported in literature [20].
Male and female patients are equally represented as
expected from an autosomal dominant pattern of inher-
itance of C1-INH deficiency.
Comparing C1-INH-HAE subjects and general Italian
population for distribution in different decades of life,
patients are less represented in the early and late de-
cades. In the literature there is no evidence regarding life
expectancy in C1-INH-HAE patients. The reduced num-
ber in the first and second decade for men can be ex-
plained with the delay in diagnosis, which is often made
after the second decade of life [1]. The reduced number
of patients in first decade can also be explained by the
absence of symptoms and by not having systematically
studied all the members of the family of every newly di-
agnosed C1-INH-HAE patient in the past. Interestingly,
from 7th decades there are fewer individuals in patients’
group compared to general population. In 1992 Cicardi
and Agostoni, analyzing the family histories of an Italian
cohort of patients with C1-INH-HAE, reported that up
to 50% of patients could have died for asphyxia [12].
This could explain the reason why in Italy C1-INH-HAE
patients have had fewer chances, compared to the gen-
eral population, to reach the late decades. We expect
that diagnostic tools and therapeutic options available
today will eliminate asphyxia as a common cause of
death for C1-INH-HAE patients. This should lead to
have patients and general population equally represented
in late decades, unless other factors may affect life ex-
pectancy. The fact that C1-INH-HAE patients are less
represented than general population in the late decades
could been related to underdiagnosis in the past. The
awareness of C1-INH-HAE has increased in recent years
and it is possible that younger patients had more oppor-
tunities to be diagnosed than elder patients.
Median age at diagnosis in our patients is 26 year old,






96 (IR 64-150) 24 (IR 14-31)
19 (IR 10-30) 20 (IR 10-30)
21(IR 12-30) 20 (IR 11-26)
Figure 1 Distribution per decades of life of C1-INH-HAE patients compared to Italian population (*p < 0.05 versus general population).
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data on delay in diagnosis (defined as time between on-
set of symptom and diagnosis), but assuming that the
large majority of patients becomes symptomatic around
puberty we could estimate a minimum delay in diagnosis
of 10 years. This result is similar to the delay in diagno-
sis reported in previous studies. In the cohort of patients
analyzed in IOS study the mean delay in diagnosis was
12.8 years [15]. In previous nationwide surveys in
France, Spain and Denmark mean delay in diagnosis was
12, 13.1 and 16.3 years, respectively [9,10,16]. Further-
more, we found a considerable difference in the median
age at diagnosis between patients with C1-INH-HAEFigure 2 Median age at diagnosis of probands from 1973 to 2013. Nu
in each 5-year-period.type I and II, 26 and 31 years respectively. This difference
was even higher in IOS study, 27.3 and 39.4 respectively.
Since diagnosis of C1-INH-HAE type II is made measur-
ing C1-INH function, the limited availability of this test
may explain why diagnosing C1-INH-HAE type II is
more difficult.
The number of new diagnosis, calculated as number of
probands to avoid the effect caused by large family groups,
increased up to 1996, likely due to an improving awareness
for this disease. Since that time the annual rate of new
diagnosis has remained stable without a trend in reduction
suggesting that we are approaching the point at which
most Italian C-INH-HAE patients have been diagnosed.mbers reported on top of histogram indicate new families diagnosed
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INH-HAE are 157 (43%). The number of de novo mu-
tants reported in literature is approximately 25% of the
families [3]. The high percentage of families with only
one subject affected likely includes de novo mutants and
patients with non-diagnosed family members. It is
mandatory after diagnosis a new patients to evaluate
other family members.
According to diagnostic criteria all patients had either
C1-INH antigen or function ≤50%. In absence of pub-
lished criteria to distinguish type I and II, we considered
as type II patients with C1-INH antigen >50% of normal.
According to these criteria, 2 patients with C1-INH anti-
gen levels slightly above 50% should have been diag-
nosed as type II, but they were classified as type I
because of, belonging to families whose other members
were type I. Similarly, we should have considered as type
I 12 patients with C1-INH antigen levels equal or
slightly below 50% of normal despite other family mem-
bers were type II. Finally, 6 patients, with personal and
family history of angioedema and C1-INH antigen
clearly below 50% of normal, had C1-INH functional
levels slightly above 50%. These rare and small discrep-
ancies between suggested diagnostic criteria and actual
data highlight the need for comprehensive and thought-
ful evaluation of clinical and laboratory findings before
placing definitive diagnosis.
The actual value of antigenic C4 in diagnosing C1-
INH-HAE has remained vague. Rosen et al in 1971 first
proved the importance of C4 consumption for detecting
C1-INH deficiency [21]. Our study demonstrates that C4
plasma levels >50% were rare in C1-INH-HAE patients
and can exclude diagnosis of C1-INH-HAE with an
error probability lower than 0.05.
Conclusion
This nationwide survey on a large number of patients
provided evidence that the estimated prevalence of
1:50,000 for C1-INH-HAE is probably close to the real
prevalence in general population. Patients with HAE-
C1-INH might have a shorter life expectancy compared
to general population. An increased awareness of the
disease, pedigree’s study, appropriate diagnosis and treat-
ment is needed to reduce the discrepancy in the distri-
bution of decade of life between general population and
HAE-C1-INH patients. Measurement of C4 antigen, a
cheap assay commonly available in laboratories, can ex-
clude diagnosis of C1-INH-HAE with an accuracy > 95%.
This parameter along with clinical data should be there-
fore considered for initial screening in differential diag-
nosis of angioedema.
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